Japan Biotech Develops 30-Minute Cure For Africa’s Sleeping Sickness
This article was originally published in PharmAsia News
Executive Summary
Japanese biotech aRigen Pharmaceuticals says it has developed a fast-acting drug to treat the sleeping sickness that plagues Africa. The company conducted its research with the University of Tokyo on the fungus-based compound ascofuranone that interferes with an oxygen-supplying enzyme. Tests on mice show the drug kills parasites in 30 minutes, but Phase I human trials have not begun. aRigen plans to license development rights to a foreign company. (Click here for more - a subscription may be required
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.